Bank of America
NTLA icon

Bank of America’s Intellia Therapeutics NTLA Stock Holding History

Bank of America’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30,000
Closed -$1.55M – 8075
2022
Q2 		$1.55M Buy
+30,000
New +$1.52M ﹤0.01% 4518

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America's NTLA Position: Q1 2026 in Review

Bank of America increased its Intellia Therapeutics (NTLA) stake by 11% in Q1 2026, buying an estimated $1.77M and bringing the position to 1,381,703 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2499.

Bank of America first reported a position in NTLA in Q2 2016 and has held it in 40 quarters since. The position peaked at $50M in Q1 2023. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Bank of America held 1,381,703 shares of Intellia Therapeutics worth $17.7M as of Q1 2026.
  • Bank of America bought 139,325 Intellia Therapeutics shares in Q1 2026, an estimated $1.77M.
  • Intellia Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2499 holding.
  • Bank of America first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 40 quarters since.
  • Bank of America's Intellia Therapeutics position peaked at $50M in Q1 2023.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.